Literature DB >> 17177205

Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma.

Patrick P Lin1, Norman Jaffe, Cynthia E Herzog, Colleen M Costelloe, Michael T Deavers, Jeana S Kelly, Shreyaskumar R Patel, John E Madewell, Valerae O Lewis, Christopher P Cannon, Robert S Benjamin, Alan W Yasko.   

Abstract

BACKGROUND: Local recurrence in Ewing sarcoma is associated with a poor prognosis. The purpose of the study was to determine the factors that predict local recurrence after surgical treatment of the primary tumor.
METHODS: Between 1990 and 2001, 64 patients underwent surgical resection of Ewing sarcoma. Surgical margins were assessed histologically and radiologically. Response to preoperative chemotherapy was determined by detailed specimen mapping. Local recurrence-free survival (LRFS) was calculated by Kaplan-Meier analysis. Multivariate analysis was performed with the Cox proportional hazards model.
RESULTS: A number of factors were found to be associated with local recurrence on univariate analysis. Patients with a good response to chemotherapy (> or = 90% tumor necrosis), had superior LRFS at 5 years (86% vs 51%, P = .015). Central site of disease was associated with an increased rate of recurrence. The LRFS at 5 years was 50% for the chest wall, 74% for pelvic/scapular, and 86% for extremity tumors (P = .083). Positive surgical margin was not a strong predictor of recurrence (P = .72). A critical analysis of minimal surgical margin based on preoperative magnetic resonance imaging (MRI) and computed tomography (CT) scans also failed to reveal an association between margin and local recurrence. In multivariate analysis, the 2 independent predictors of local recurrence were histological response to chemotherapy and central site of disease.
CONCLUSION: Local recurrence after surgical resection is a complex phenomenon. An important predictive factor is the response to chemotherapy. In the current study, this seems to have the largest impact. Central site of disease may be a second independent predictive factor. (c) 2007 American Cancer Society.

Entities:  

Mesh:

Year:  2007        PMID: 17177205     DOI: 10.1002/cncr.22412

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

Review 1.  Very late local recurrence of Ewing's sarcoma--can you ever say 'cured'? A report of two cases and literature review.

Authors:  S A Hanna; L A David; P D Gikas; A J Tindall; S R Cannon; T W R Briggs
Journal:  Ann R Coll Surg Engl       Date:  2008-10       Impact factor: 1.891

2.  18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different.

Authors:  Louie L Gaston; Claudia Di Bella; John Slavin; Rodney J Hicks; Peter F M Choong
Journal:  Skeletal Radiol       Date:  2011-02-06       Impact factor: 2.199

Review 3.  Imaging pediatric bone sarcomas.

Authors:  Sue C Kaste
Journal:  Radiol Clin North Am       Date:  2011-06-16       Impact factor: 2.303

4.  [18F]FDG PET/CT quantitative parameters for the prediction of histological response to induction chemotherapy and clinical outcome in patients with localised bone and soft-tissue Ewing sarcoma.

Authors:  Alessio Annovazzi; Virginia Ferraresi; Vincenzo Anelli; Renato Covello; Sabrina Vari; Carmine Zoccali; Roberto Biagini; Rosa Sciuto
Journal:  Eur Radiol       Date:  2021-03-13       Impact factor: 5.315

5.  Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskeletal Ewing Sarcoma.

Authors:  David Boyce-Fappiano; B Ashleigh Guadagnolo; Ravin Ratan; Wei-Lien Wang; Michael J Wagner; Shreyaskumar Patel; John A Livingston; Patrick P Lin; Kevin Diao; Devarati Mitra; Ahsan Farooqi; Alexander J Lazar; Christina L Roland; Andrew J Bishop
Journal:  Oncologist       Date:  2020-12-14

6.  Sixty percent 10-year survival of patients with chondrosarcoma after local recurrence.

Authors:  Patrick P Lin; Mohammed D Alfawareh; Akihiko Takeuchi; Bryan S Moon; Valerae O Lewis
Journal:  Clin Orthop Relat Res       Date:  2012-03       Impact factor: 4.176

7.  Localized Adult Ewing Sarcoma: Favorable Outcomes with Alternating Vincristine, Doxorubicin, Cyclophosphamide, and Ifosfamide, Etoposide (VDC/IE)-Based Multimodality Therapy.

Authors:  Jennifer L Pretz; Constance M Barysauskas; Suzanne George; Jason L Hornick; Chandrajit P Raut; Yen-Lin E Chen; Karen J Marcus; Edwin Choy; Francis Hornicek; John E Ready; Thomas F DeLaney; Elizabeth H Baldini
Journal:  Oncologist       Date:  2017-05-26

8.  Prognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection.

Authors:  Hubert Y Pan; Ajaykumar Morani; Wei-Lien Wang; Kenneth R Hess; Arnold C Paulino; Joseph A Ludwig; Patrick P Lin; Najat C Daw; Anita Mahajan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-03-12       Impact factor: 7.038

9.  Timing of surgery and the role of adjuvant radiotherapy in ewing sarcoma of the chest wall: a single-institution experience.

Authors:  Jason W Denbo; W Shannon Orr; Yanan Wu; Jianrong Wu; Catherine A Billups; Fariba Navid; Bhaskar N Rao; Andrew M Davidoff; Matthew J Krasin
Journal:  Ann Surg Oncol       Date:  2012-07-03       Impact factor: 5.344

10.  Comparison of Latino and non-Latino patients with Ewing sarcoma.

Authors:  Jeremy Sharib; Andrew Horvai; Florette K Gray Hazard; Heike Daldrup-Link; Robert Goldsby; Neyssa Marina; Steven G DuBois
Journal:  Pediatr Blood Cancer       Date:  2013-08-23       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.